07:00 , Sep 29, 2014 |  BC Week In Review  |  Clinical News

AVI-7537 regulatory update

EMA's CHMP began a formal review of the available scientific information on Ebola treatments under development. The agency said its goal is to provide an overview of the current state of knowledge about therapies under...
16:18 , Sep 26, 2014 |  BC Extra  |  Politics & Policy

CHMP to review Ebola treatments

EMA has started a review of investigational Ebola treatments. The agency said its goal is to support decision making by health authorities as they decide whether to use experimental treatments in infected patients. The agency...
07:00 , Sep 25, 2014 |  BC Innovations  |  Cover Story

Interrupting Ebola

The 2014 Ebola outbreak is the largest in the disease's history and the first in West Africa, where it has reached multiple countries. Although an approved therapy looks far away, five of seven patients given...
07:00 , Sep 15, 2014 |  BioCentury  |  Product Development

Ebola realities

Hope that experimental Ebola vaccines and therapies might help contain the current outbreak is sliding into hype as public health officials exaggerate how quickly new products could be deployed and minimize the uncertainties inherent in...
07:00 , Aug 11, 2014 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Biodefense company Emergent BioSolutions Inc. (NYSE:EBS) was up $0.44 to $22.47 last week after submitting a BLA to FDA for Anthrax immune globulin IV (AIGIV) to treat inhaled anthrax. AIGIV is being developed...
07:00 , Jul 24, 2014 |  BC Innovations  |  Cover Story

It is an RNA world

RNA-based molecules have redefined the universe of tractable targets by putting virtually anything that is gene encoded within reach of a disease-modifying agent. This redefinition has launched RNA as the biotech industry's third drug modality....
07:00 , Oct 8, 2012 |  BC Week In Review  |  Company News

Sarepta Therapeutics, Tekmira, U.S. Department of Defense infectious, drug delivery news

The DoD will continue funding only Tekmira's Ebola medical countermeasure R&D contract after its and Sarepta's contracts were suspended in August due to government budget constraints. The government selected the TKM-Ebola program from Tekmira, which...
00:27 , Oct 3, 2012 |  BC Extra  |  Company News

DoD to continue funding Tekmira's Ebola program

The U.S. Department of Defense said it will continue funding only one of two Ebola medical countermeasure R&D contracts that were suspended in August due to government budget constraints. The government selected the TKM-Ebola program...
07:00 , Sep 24, 2012 |  BC Week In Review  |  Clinical News

AVI-7288 regulatory update

FDA granted Fast Track designation for Sarepta's AVI-7288 to treat Marburg virus infection and AVI-7537 to treat Ebola virus infection. Sarepta is developing the compounds, which are single oligomer nucleic acid analog based on morpholino-modified...
07:00 , Sep 24, 2012 |  BC Week In Review  |  Clinical News

AVI-7537 regulatory update

FDA granted Fast Track designation for Sarepta's AVI-7288 to treat Marburg virus infection and AVI-7537 to treat Ebola virus infection. Sarepta is developing the compounds, which are single oligomer nucleic acid analog based on morpholino-modified...